Abstract
Outcomes for relapsed and refractory acute lymphoblastic leukemia (ALL) remain poor. With the advent of targeted monoclonal antibodies and antibody constructs, these outcomes have been significantly improved both in the frontline and salvage setting. These targets include a bispecific antibody that targets both CD3 and CD19, known as blinatumomab, as well as a conjugated antibody that targets CD22, known as inotuzumab ozogamicin. These agents have been thoroughly studied and successively approved for use as monotherapy, however, more recently they have been incorporated in combination or sequentially with cytotoxic chemotherapy. In this chapter, we will discuss the role that these monoclonal antibodies play as monotherapy and in combination in the treatment of ALL in the salvage setting, and how they continue to transform the treatment management of relapsed and refractory ALL.
Original language | English (US) |
---|---|
Article number | 101225 |
Journal | Best Practice and Research: Clinical Haematology |
Volume | 33 |
Issue number | 4 |
DOIs | |
State | Published - Dec 2020 |
Keywords
- Acute lymphoblastic leukemia
- Blinatumomab
- Inotuzumab
- Monoclonal antibody
ASJC Scopus subject areas
- Oncology
- Clinical Biochemistry